

European Statistical Meeting

Generating evidence for Health Technology Assessment

Thursday 25th September 2014, Berlin

The importance of HTA has increased substantially over the last few years. In order to obtain reimbursement, it has become critical for manufacturers to provide additional evidence about their products in a real-world setting to satisfy the requirements of the various national HTA bodies.

This meeting will provide a forum to hear about the latest developments in the applications of HTA methods from representatives from European regulatory bodies, and from practitioners in the pharmaceutical industry and academia

9:30am to 5:30pm

Presenters include:

Ralf Bender, IQWiG	<i>Biometrical issues in the framework of benefit assessment</i>
Chrissie Fletcher, Amgen	<i>Subgroup analyses for regulatory and HTA submissions</i>
Omar Dabbous, GSK	<i>Analytical Strategy, Credibility and Rigor of Evidence for HTA</i>
Tim Auton, Astellas	<i>Designing better observational studies: The role of the pharmaceutical statistician</i>
Christoph Gerlinger, Bayer	<i>Deriving minimally important difference for PRO data</i>
Marie-Ange Paget, Lilly	<i>Meeting local HTA requirements – challenges for the HTA statistician</i>
Fred Sörenson, Xcenda	<i>Applying Real-World Data in HTA – Why one size does not fit all</i>



Venue

Bayer HealthCare Pharmaceuticals
Müllerstrasse 178
13352 Berlin
Germany

Registration Costs

Fee includes lunch & refreshments

Registration before 22 August

Industry €160
Academic €100

Registration after 22 August

Industry €190
Academic €120

TO REGISTER PLEASE GO TO:

www.efspi.org

OR

Contact:

EFSPI Secretariat
Tel: +44 (0)1625 664549
efspi@kingstonsmith.co.uk